Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannara Biotech (V.LOVE) Reports Fourth Quarter and 2023 Fiscal Year Results (click to learn more) Pulsar’s New Presentation Includes New Images for the Passive Seismic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biomind Labs Ord Shs N.BMND

Alternate Symbol(s):  BMNDF

Healthcare
Biomind Labs Inc. is a Canada-based biotech research and development company. The Company is primarily engaged in biotech platform that integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production with special focus on scientific research, clinical trials and in jurisdictions that open a fast track in the molecule to market lifecycle... see more

Recent & Breaking News (NEO:BMND)

Biomind Labs Provides Corporate Update

Business Wire September 27, 2023

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications

Business Wire September 14, 2023

Biomind Announces Voting Results From the 2023 Annual Meeting of Shareholders

Business Wire June 30, 2023

Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer's Disease With a Proprietary formulation Based On 5-MeO-DMT

Business Wire April 25, 2023

Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax(TM)

Business Wire March 31, 2023

Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer's Disease

Business Wire December 28, 2022

Biomind Labs Announces FDA Investigational New Drug Clearance for Its New Chemical Entity Triptax(TM) Targeting Treatment-Resistant Depression and Reports Third Quarter Financial Results

Business Wire November 14, 2022

Biomind Labs (NEO:BMND) sees positive results from its phase 2 depression treatment trial

Jonathon Brown November 4, 2022

Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression

Business Wire November 4, 2022

Biomind Labs Announces Pre-IND Meeting Request Granted by FDA for Its New Chemical Entity Triptax(TM) Targeting Treatment-Resistant Depression

Business Wire October 11, 2022

Biomind Labs and Queen's University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System

Business Wire September 27, 2022

Biomind Labs (NEO:BMND) completes phase II DMT trial

Caroline Egan  September 21, 2022

Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Business Wire September 21, 2022

Biomind Labs Appoints Former FDA Director Dr. Thomas Laughren as Medical Advisor for Clinical Trials

Business Wire July 27, 2022

Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Treatment of Depression and Anxiety in Alzheimer's Disease

Business Wire May 26, 2022

Biomind Labs to Argument Which Psychedelic Medicines Will Lead the Industry Into Its Next Phase of Evolution at The National Gallery in London

Business Wire May 9, 2022

The StockTalk Cannabis Report: April 29, 2022

Dave Jackson April 29, 2022

The World’s 1st Trial Testing Inhaled DMT Formulation

Stockhouse Editorial April 27, 2022

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Business Wire April 26, 2022

Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London

Business Wire April 12, 2022